- Report
- August 2024
- 175 Pages
Global
From €4775EUR$5,000USD£3,993GBP
- Report
- October 2024
- 195 Pages
Global
From €3386EUR$3,545USD£2,831GBP
€3762EUR$3,939USD£3,146GBP
- Report
- March 2025
- 175 Pages
Global
From €4288EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4288EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4288EUR$4,490USD£3,586GBP
- Report
- May 2024
- 138 Pages
Global
From €6207EUR$6,499USD£5,190GBP
- Report
- March 2024
- 159 Pages
Global
From €7593EUR$7,950USD£6,349GBP
- Report
- March 2025
- 50 Pages
Global
From €2531EUR$2,650USD£2,116GBP
Atenolol is a beta-blocker drug used to treat cardiovascular diseases such as hypertension, angina, and arrhythmias. It works by blocking the action of certain natural chemicals in the body, such as epinephrine, that affect the heart and blood vessels. Atenolol is usually taken once or twice daily, with or without food. It is available in tablet, capsule, and liquid form.
Atenolol is a widely used drug in the cardiovascular market, as it is effective in treating a variety of conditions. It is also relatively inexpensive compared to other drugs in the same class. Additionally, it has a low risk of side effects, making it a popular choice for many patients.
In the Atenolol market, some of the major players include Pfizer, Novartis, Merck, and GlaxoSmithKline. Other companies such as Mylan, Teva, and Sandoz also produce generic versions of the drug. Show Less Read more